We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.

Submit your research today!

Expert Opinion on Investigational Drugs – Hepatocellular carcinoma

About the special issue

This issue will offer in depth analyses of new molecular targets and drug therapies for hepatocellular carcinoma (HCC); it will provide a birdseye view of key innovations in this rapidly changing field. HCC comprises the majority of liver cancer cases. A significant percentage of HCCs present with potentially actionable mutations, but translation of this knowledge into the clinic is a work in progress. A handful of systemic therapies are available in the clinic while current clinical trials are examining combination therapies which comprise checkpoint inhibitors and tyrosine kinase inhibitors (TKIs) or anti-VEGF approaches, or immunotherapy combinations. The outcomes of these trials could transform the therapeutic landscape and impact outcomes for patients. Be sure to keep up to date with Expert Opinion on Investigational Drugs.

Submission information

Submission Deadlines:

Standard track: 01/12/2022

Rapid track: 15/12/2022

Fast track: 22/03/2023


Accelerated Publication

Publish in 3 – 5 weeks from submission

Submission to acceptance: 2 – 3 weeks
1 – 2 weeks for peer review
1 week for author revision

Acceptance to online publication: 1 – 2 weeks, with proofs within 5 working days and 48 hours for author review

Cost per article: $7000 / €6200 / £5500

Publish in 7 – 9 weeks from submission

Submission to acceptance: 5 – 6 weeks
3 – 4 weeks for peer review
2 weeks for author revision

Acceptance to online publication: 2 – 3 weeks, with proofs within 10 working days

Cost per article: $3900 / €3400 / £3000


By publishing in Expert Opinion on Investigational Drugs you will:

  • Gain recognition from an international audience and increase your opportunities for future collaboration

  • Receive 50 free e-prints & promotional tips on promoting your article courtesy of our Author Services site

  • Immediately see the impact of your research made in the community by tracking downloads, citations, and the Altmetric Score of your article on My Authored Works

  • Increase the discoverability of your research with MEDLINE listings and more

PLS Plain Language Summary

When you are ready to submit your article, communicate the significance of your original research in a clear language to a broad audience using Plain Language Summary.

Conference Supplements

Considering publishing multimedia content? Research shows an increase in engagement and visibility when your research is accompanied by multimedia. Get in touch with Senior Editor Priti Nagda to discuss any specific requests.

Accelerated Publication Banner

Want to keep competitive advantage by getting your discoveries to market quickly? Or is time critical in your publishing strategy? Discover our Accelerated Publication options to help get your research into a high-quality, peer-reviewed journal, fast.

Expert Collection Editorial Calendar

Explore the 2022 Expert Collection Calendar of special themed issues. Each special themed issue will be a one-stop resource for those interested in the field. By publishing your article, you can reap the benefits of the collection’s visibility and high impact.

Conference Supplements

Conference material supplements can include the following article types: Poster extracts, Conference abstracts, and Presentation extracts. Open access conference material supplements are peer-reviewed, permanent, and citable.

Editing Services Banner

Pre-submission manuscript preparation can help you maximize the impact of your research and improve the quality of your manuscript. Services include English Language Editing, Scientific Editing, Manuscript formatting, and many more!

We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.